Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Epithelial-mesenchymal transition (EMT) is an embryonic program that is reactivated in cancer and regulates the invasion and metastasis of tumor cells.
Zinc finger E-box binding homeobox 2
(
ZEB2
) induces EMT by upregulating matrix metalloproteinases (MMP), yet MMP genes lack
ZEB2
binding motif in their promoters. Recently, expression of MMPs was associated to the activation of ETS1 transcription factor; however, a link between
ZEB2
and ETS proto-oncogene 1, transcription factor (ETS1) remains to be elucidated. Hence, we investigated the transcriptional regulation of ETS1 by
ZEB2
after our initial observation that
ZEB2
and ETS1 are coexpressed in
hepatocellular carcinoma
cells (HCCs). Chromatin immunoprecipitation and luciferase reporter assays clearly showed that
ZEB2
binds to E-box sequences on the promoter of ETS1. Elevated expression of ETS1 was found in DLD-
ZEB2
and A431-
ZEB2
inducible systems, and knockdown of
ZEB2
caused an explicit downregulation of ETS1 in shZEB2-SNU398 and shZEB2-SK-HEP-1 cells. Repression of ETS1 expression in
ZEB2
-induced conditions substantially impaired the migration and invasive capacities of DLD1 cells. Mechanistically, knockdown of ETS1 in
ZEB2
-expressing cells resulted in the downregulation of established
ZEB2
targets TWIST and MMP9. Correlation analyses in HCC lines, cancer complementary DNA arrays, and The Cancer Genome Atlas RNA-sequencing data set revealed that
ZEB2
and ETS1 are coexpressed, and their expressions in human tumors show a highly significant positive correlation. Our results demonstrated that
ZEB2
acts as an upstream regulator of ETS1 and, in turn, ETS1 maintains
ZEB2
-induced EMT. These findings add another level of complexity to the understanding of
ZEB2
in the invasion and metastasis of cancer cells, and put
ZEB2
/ETS1 axis as a novel therapeutic target in human malignancies.
...
PMID:ETS1 is coexpressed with ZEB2 and mediates ZEB2-induced epithelial-mesenchymal transition in human tumors. 3079 Mar 40